 |
Title
|
|
|
|
Phase 
|
|
|
|
Protocol IDs
|
|
|
| |
Aromatase Inhibitor Clinical Trial
|
|
|
|
Phase IV
|
|
|
|
0412-14
UO1-GM61373-06, NCT00228956
|
|
| |
Pharmacogenetics as a Predictor of Toxicity in Pre-Menopausal Women Receiving Doxorubicin and Cyclophosphamide in Early Breast Cancer
|
|
|
|
Phase IV
|
|
|
|
0501-37
NCT00352872
|
|
| |
Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-Menopausal Women With Breast Cancer
|
|
|
|
Phase IV
|
|
|
|
CFEM345DUS59
NCT00688909
|
|
| |
Using the Conture® Multi-Lumen Balloon to Deliver Accelerated Partial Breast Brachytherapy
|
|
|
|
Phase IV
|
|
|
|
SENORX-S07-002
NCT00699101
|
|
| |
Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis
|
|
|
|
Phase III, Phase II
|
|
|
|
20050113
NCT00243685
|
|
| |
Letrozole After Tamoxifen in Treating Women With Breast Cancer
|
|
|
|
Phase III
|
|
|
|
CAN-NCIC-MA17
CALGB-49805, E-JMA17, EORTC-10983, IBCSG-BIG97-01, NCCTG-JMA17, SWOG-JMA17, JRF-Vor-Int-10, NCCTG-CAN-MA17, SWOG-CAN-MA17, NCT00003140, JMA17, MA17
|
|
| |
Combination Chemotherapy in Treating Women With Breast Cancer
|
|
|
|
Phase III
|
|
|
|
CALGB-40101
CALGB-40101, NCT00041119
|
|
| |
Suppression of Ovarian Function Plus Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
|
|
|
|
Phase III
|
|
|
|
IBCSG-2402
BIG-2-02, CALGB-IBCSG-2402, CAN-NCIC-IBCSG-2402, NCCTG-IBCSG-2402, NSABP-IBCSG-2402, SWOG-IBCSG-2402, NABCI-IBCSG-2402, UCLA-0403024-01, EU-20334, IBCSG-24-02, NCT00066690, EUDRACT-2004-000166-13
|
|
| |
Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer
|
|
|
|
Phase III
|
|
|
|
SWOG-S0221
S0221, NCT00070564
|
|
| |
Adjuvant Chemotherapy in Treating Women Who Have Undergone Resection for Relapsed Breast Cancer
|
|
|
|
Phase III
|
|
|
|
IBCSG-27-02
BIG-1-02, EU-20320, NCT00074152, NSABP-B-37, EUDRACT-2005-001484-64
|
|
